Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H20N2S.ClH |
Molecular Weight | 332.891 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1
InChI
InChIKey=IEISBKIVLDXSMZ-UHFFFAOYSA-N
InChI=1S/C18H20N2S.ClH/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20;/h2-9,14H,10-13H2,1H3;1H
DescriptionSources: http://www.drugbank.ca/drugs/DB00902Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/methdilazine-hydrochloride.html
Sources: http://www.drugbank.ca/drugs/DB00902
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/methdilazine-hydrochloride.html
Methdilazine is a phenothiazine compound with antihistaminic activity. Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Mycobacterium spp. growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/8103345 |
|||
Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00902 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TACARYL Approved UseUsed in the treatment of pruritus associated with pityriasis rosea. Launch Date1981 |
PubMed
Title | Date | PubMed |
---|---|---|
Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents. | 1988 Jul |
|
Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. | 1993 Jun |
|
Altered membrane permeability as the basis of bactericidal action of methdilazine. | 1998 Jul |
|
Four simple procedures for the assay of methdilazine in bulk drug and in tablets and syrup using potassium iodate. | 2003 Apr |
|
A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. | 2010 Apr 8 |
Patents
Sample Use Guides
Usual adult and adolescent dose
Oral, 8 mg every six to twelve hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8103345
Methdilazine (Md) could inhibit various Mycobacterium spp. at 5-15 ug/ml concentrations in vitro as well as in vivo.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000085950
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
91121
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000486
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200959
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
C63950
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
C044642
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
5192
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
T0GSO02UEZ
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
1408000
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
DTXSID3025548
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
SUB03213MIG
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
214-967-3
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
169091
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
14676
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
1229-35-2
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | |||
|
m7306
Created by
admin on Fri Dec 15 16:14:31 GMT 2023 , Edited by admin on Fri Dec 15 16:14:31 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD